Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 12 March, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 543960 | NSE: CONCORDBIO

Concord Biotech Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 11, 2025, 11:31 pm

Market Cap 17,200 Cr.
Current Price 1,644
High / Low 2,664/1,327
Stock P/E52.4
Book Value 152
Dividend Yield0.53 %
ROCE27.9 %
ROE20.9 %
Face Value 1.00
PEG Ratio-1.55

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Concord Biotech Ltd

Competitors of Concord Biotech Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Concord Biotech Ltd 17,200 Cr. 1,644 2,664/1,32752.4 1520.53 %27.9 %20.9 % 1.00
Industry Average17,200.00 Cr1,644.0052.40152.000.53%27.90%20.90%1.00

All Competitor Stocks of Concord Biotech Ltd

Quarterly Result

MetricJun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 181159241273195262241319216310244
Expenses 116121129144123143135185135174146
Operating Profit 6538112129721191061348113798
OPM % 36%24%46%47%37%45%44%42%38%44%40%
Other Income 8691278811101015
Interest 11111100000
Depreciation 1413141413131414131313
Profit before tax 5830106126651131001317813399
Tax % 26%26%26%26%25%25%26%26%25%26%25%
Net Profit 4322799448847597589974
EPS in Rs 45.322.147.568.944.638.087.139.295.579.437.08

Last Updated: February 28, 2025, 12:25 pm

Below is a detailed analysis of the quarterly data for Concord Biotech Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹244.00 Cr.. The value appears to be declining and may need further review. It has decreased from 310.00 Cr. (Sep 2024) to ₹244.00 Cr., marking a decrease of 66.00 Cr..
  • For Expenses, as of Dec 2024, the value is ₹146.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 174.00 Cr. (Sep 2024) to ₹146.00 Cr., marking a decrease of 28.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹98.00 Cr.. The value appears to be declining and may need further review. It has decreased from 137.00 Cr. (Sep 2024) to ₹98.00 Cr., marking a decrease of 39.00 Cr..
  • For OPM %, as of Dec 2024, the value is 40.00%. The value appears to be declining and may need further review. It has decreased from 44.00% (Sep 2024) to 40.00%, marking a decrease of 4.00%.
  • For Other Income, as of Dec 2024, the value is ₹15.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Sep 2024) to ₹15.00 Cr., marking an increase of ₹5.00 Cr..
  • For Interest, as of Dec 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹13.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 13.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹99.00 Cr.. The value appears to be declining and may need further review. It has decreased from 133.00 Cr. (Sep 2024) to ₹99.00 Cr., marking a decrease of 34.00 Cr..
  • For Tax %, as of Dec 2024, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Sep 2024) to 25.00%, marking a decrease of 1.00%.
  • For Net Profit, as of Dec 2024, the value is ₹74.00 Cr.. The value appears to be declining and may need further review. It has decreased from 99.00 Cr. (Sep 2024) to ₹74.00 Cr., marking a decrease of 25.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 7.08. The value appears to be declining and may need further review. It has decreased from ₹9.43 (Sep 2024) to 7.08, marking a decrease of ₹2.35.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 1:31 pm

MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 3404365126177138531,0171,089
Expenses 195256308289439509585639
Operating Profit 145180205328274344432450
OPM % 43%41%40%53%38%40%42%41%
Other Income 1817311423353446
Interest 11116531
Depreciation 1819212850545453
Profit before tax 144178213313241320409442
Tax % 30%33%21%25%26%26%26%
Net Profit 100118169235179238305328
EPS in Rs 105.66124.48177.65247.44187.7622.7629.1331.37
Dividend Payout % 0%21%22%0%3%30%30%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)18.00%43.22%39.05%-23.83%32.96%28.15%
Change in YoY Net Profit Growth (%)0.00%25.22%-4.17%-62.88%56.79%-4.81%

Concord Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2018-2019 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:%
5 Years:18%
3 Years:18%
TTM:12%
Compounded Profit Growth
10 Years:%
5 Years:20%
3 Years:9%
TTM:9%
Stock Price CAGR
10 Years:%
5 Years:%
3 Years:%
1 Year:16%
Return on Equity
10 Years:%
5 Years:21%
3 Years:19%
Last Year:21%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 5:31 pm

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 1010101010101010
Reserves 5856737619901,0981,2821,5151,580
Borrowings 22952896232103
Other Liabilities 697211894144191164171
Total Liabilities 6857639411,1831,3131,5151,6991,765
Fixed Assets 189230240546573593575558
CWIP 3191411874173211249
Investments 15122919914274138244276
Other Assets 343285361477592611668682
Total Assets 6857639411,1831,3131,5151,6991,765

Below is a detailed analysis of the balance sheet data for Concord Biotech Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹10.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹1,580.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1,515.00 Cr. (Mar 2024) to ₹1,580.00 Cr., marking an increase of 65.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹3.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹10.00 Cr. (Mar 2024) to ₹3.00 Cr., marking a decrease of 7.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹171.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹164.00 Cr. (Mar 2024) to ₹171.00 Cr., marking an increase of 7.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹1,765.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹1,699.00 Cr. (Mar 2024) to ₹1,765.00 Cr., marking an increase of 66.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹558.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹575.00 Cr. (Mar 2024) to ₹558.00 Cr., marking a decrease of 17.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹249.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹211.00 Cr. (Mar 2024) to ₹249.00 Cr., marking an increase of 38.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹276.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹244.00 Cr. (Mar 2024) to ₹276.00 Cr., marking an increase of 32.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹682.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹668.00 Cr. (Mar 2024) to ₹682.00 Cr., marking an increase of 14.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹1,765.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1,699.00 Cr. (Mar 2024) to ₹1,765.00 Cr., marking an increase of 66.00 Cr..

Notably, the Reserves (₹1,580.00 Cr.) exceed the Borrowings (3.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +79155167207246265
Cash from Investing Activity +-42-114-195-112-158-155
Cash from Financing Activity +-37-4331-100-85-99
Net Cash Flow0-13-4312

Free Cash Flow

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow123.00171.00153.00239.00212.00312.00422.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days236133131105119117125
Inventory Days381310312503434430331
Days Payable210112201152185190150
Cash Conversion Cycle407331242456368357306
Working Capital Days275186160196179163169
ROCE %27%25%32%21%26%28%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters44.08%44.08%44.08%44.08%44.08%44.08%
FIIs7.30%7.00%6.49%7.11%8.10%8.33%
DIIs8.12%8.40%8.41%10.35%9.82%9.65%
Public40.50%40.52%41.03%38.46%38.02%37.93%
No. of Shareholders1,00,92787,48683,29680,73784,29882,004

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
HSBC Small Cap Fund - Regular Plan853,9620.97129.87188,2862025-03-10353.55%
Edelweiss Small Cap Fund264,7051.2840.26188,2862025-03-1040.59%
Invesco India Smallcap Fund257,6291.0739.18188,2862025-03-1036.83%
Edelweiss Mid Cap Fund236,2320.735.93188,2862025-03-1025.46%
Franklin India Smaller Companies Fund236,0400.3135.9188,2862025-03-1025.36%
Edelweiss Recently Listed IPO Fund215,0003.6432.7188,2862025-03-1014.19%
Invesco India ELSS Tax Saver Fund188,2861.1328.63188,2862025-03-100%
Invesco India Multicap Fund169,6800.8225.8188,2862025-03-10-9.88%
Franklin India Opportunities Fund169,1340.8725.72188,2862025-03-10-10.17%
Edelweiss Large & Mid Cap Fund138,9740.7421.14188,2862025-03-10-26.19%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22
FaceValue 1.001.0010.00
Basic EPS (Rs.) 29.4522.9516.72
Diluted EPS (Rs.) 29.4522.9516.72
Cash EPS (Rs.) 34.2527.93240.38
Book Value[Excl.RevalReserv]/Share (Rs.) 145.93123.311159.99
Book Value[Incl.RevalReserv]/Share (Rs.) 145.93123.311159.99
Revenue From Operations / Share (Rs.) 97.2181.55749.62
PBDIT / Share (Rs.) 44.4836.19311.96
PBIT / Share (Rs.) 39.3631.02259.33
PBT / Share (Rs.) 39.1130.59253.57
Net Profit / Share (Rs.) 29.1322.76187.76
NP After MI And SOA / Share (Rs.) 29.4522.95183.93
PBDIT Margin (%) 45.7544.3741.61
PBIT Margin (%) 40.4838.0434.59
PBT Margin (%) 40.2337.5133.82
Net Profit Margin (%) 29.9627.9125.04
NP After MI And SOA Margin (%) 30.2928.1424.53
Return on Networth / Equity (%) 20.1818.6115.85
Return on Capital Employeed (%) 26.4124.5421.30
Return On Assets (%) 18.1115.8513.32
Long Term Debt / Equity (X) 0.000.000.02
Total Debt / Equity (X) 0.000.020.05
Asset Turnover Ratio (%) 0.630.600.00
Current Ratio (X) 6.303.794.08
Quick Ratio (X) 4.842.692.82
Inventory Turnover Ratio (X) 0.870.820.00
Dividend Payout Ratio (NP) (%) 23.1922.3140.31
Dividend Payout Ratio (CP) (%) 19.7518.2131.34
Earning Retention Ratio (%) 76.8177.6959.69
Cash Earning Retention Ratio (%) 80.2581.7968.66
Interest Coverage Ratio (X) 182.3583.9454.11
Interest Coverage Ratio (Post Tax) (X) 120.4153.8033.56
Enterprise Value (Cr.) 15881.240.000.00
EV / Net Operating Revenue (X) 15.620.000.00
EV / EBITDA (X) 34.130.000.00
MarketCap / Net Operating Revenue (X) 15.660.000.00
Retention Ratios (%) 76.8077.6859.68
Price / BV (X) 10.430.000.00
Price / Net Operating Revenue (X) 15.660.000.00
EarningsYield 0.010.000.00

After reviewing the key financial ratios for Concord Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 29.45. This value is within the healthy range. It has increased from 22.95 (Mar 23) to 29.45, marking an increase of 6.50.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 29.45. This value is within the healthy range. It has increased from 22.95 (Mar 23) to 29.45, marking an increase of 6.50.
  • For Cash EPS (Rs.), as of Mar 24, the value is 34.25. This value is within the healthy range. It has increased from 27.93 (Mar 23) to 34.25, marking an increase of 6.32.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 145.93. It has increased from 123.31 (Mar 23) to 145.93, marking an increase of 22.62.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 145.93. It has increased from 123.31 (Mar 23) to 145.93, marking an increase of 22.62.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 97.21. It has increased from 81.55 (Mar 23) to 97.21, marking an increase of 15.66.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 44.48. This value is within the healthy range. It has increased from 36.19 (Mar 23) to 44.48, marking an increase of 8.29.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 39.36. This value is within the healthy range. It has increased from 31.02 (Mar 23) to 39.36, marking an increase of 8.34.
  • For PBT / Share (Rs.), as of Mar 24, the value is 39.11. This value is within the healthy range. It has increased from 30.59 (Mar 23) to 39.11, marking an increase of 8.52.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 29.13. This value is within the healthy range. It has increased from 22.76 (Mar 23) to 29.13, marking an increase of 6.37.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 29.45. This value is within the healthy range. It has increased from 22.95 (Mar 23) to 29.45, marking an increase of 6.50.
  • For PBDIT Margin (%), as of Mar 24, the value is 45.75. This value is within the healthy range. It has increased from 44.37 (Mar 23) to 45.75, marking an increase of 1.38.
  • For PBIT Margin (%), as of Mar 24, the value is 40.48. This value exceeds the healthy maximum of 20. It has increased from 38.04 (Mar 23) to 40.48, marking an increase of 2.44.
  • For PBT Margin (%), as of Mar 24, the value is 40.23. This value is within the healthy range. It has increased from 37.51 (Mar 23) to 40.23, marking an increase of 2.72.
  • For Net Profit Margin (%), as of Mar 24, the value is 29.96. This value exceeds the healthy maximum of 10. It has increased from 27.91 (Mar 23) to 29.96, marking an increase of 2.05.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 30.29. This value exceeds the healthy maximum of 20. It has increased from 28.14 (Mar 23) to 30.29, marking an increase of 2.15.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 20.18. This value is within the healthy range. It has increased from 18.61 (Mar 23) to 20.18, marking an increase of 1.57.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 26.41. This value is within the healthy range. It has increased from 24.54 (Mar 23) to 26.41, marking an increase of 1.87.
  • For Return On Assets (%), as of Mar 24, the value is 18.11. This value is within the healthy range. It has increased from 15.85 (Mar 23) to 18.11, marking an increase of 2.26.
  • For Long Term Debt / Equity (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 23) which recorded 0.00.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.00. This value is within the healthy range. It has decreased from 0.02 (Mar 23) to 0.00, marking a decrease of 0.02.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.63. It has increased from 0.60 (Mar 23) to 0.63, marking an increase of 0.03.
  • For Current Ratio (X), as of Mar 24, the value is 6.30. This value exceeds the healthy maximum of 3. It has increased from 3.79 (Mar 23) to 6.30, marking an increase of 2.51.
  • For Quick Ratio (X), as of Mar 24, the value is 4.84. This value exceeds the healthy maximum of 2. It has increased from 2.69 (Mar 23) to 4.84, marking an increase of 2.15.
  • For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.87. This value is below the healthy minimum of 4. It has increased from 0.82 (Mar 23) to 0.87, marking an increase of 0.05.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 23.19. This value is within the healthy range. It has increased from 22.31 (Mar 23) to 23.19, marking an increase of 0.88.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 19.75. This value is below the healthy minimum of 20. It has increased from 18.21 (Mar 23) to 19.75, marking an increase of 1.54.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 76.81. This value exceeds the healthy maximum of 70. It has decreased from 77.69 (Mar 23) to 76.81, marking a decrease of 0.88.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 80.25. This value exceeds the healthy maximum of 70. It has decreased from 81.79 (Mar 23) to 80.25, marking a decrease of 1.54.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 182.35. This value is within the healthy range. It has increased from 83.94 (Mar 23) to 182.35, marking an increase of 98.41.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 120.41. This value is within the healthy range. It has increased from 53.80 (Mar 23) to 120.41, marking an increase of 66.61.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 15,881.24. It has increased from 0.00 (Mar 23) to 15,881.24, marking an increase of 15,881.24.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 15.62. This value exceeds the healthy maximum of 3. It has increased from 0.00 (Mar 23) to 15.62, marking an increase of 15.62.
  • For EV / EBITDA (X), as of Mar 24, the value is 34.13. This value exceeds the healthy maximum of 15. It has increased from 0.00 (Mar 23) to 34.13, marking an increase of 34.13.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 15.66. This value exceeds the healthy maximum of 3. It has increased from 0.00 (Mar 23) to 15.66, marking an increase of 15.66.
  • For Retention Ratios (%), as of Mar 24, the value is 76.80. This value exceeds the healthy maximum of 70. It has decreased from 77.68 (Mar 23) to 76.80, marking a decrease of 0.88.
  • For Price / BV (X), as of Mar 24, the value is 10.43. This value exceeds the healthy maximum of 3. It has increased from 0.00 (Mar 23) to 10.43, marking an increase of 10.43.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 15.66. This value exceeds the healthy maximum of 3. It has increased from 0.00 (Mar 23) to 15.66, marking an increase of 15.66.
  • For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 23) to 0.01, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Concord Biotech Ltd as of March 12, 2025 is: ₹1,338.77

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Concord Biotech Ltd is Overvalued by 18.57% compared to the current share price 1,644.00

Intrinsic Value of Concord Biotech Ltd as of March 12, 2025 is: 885.76

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Concord Biotech Ltd is Overvalued by 46.12% compared to the current share price 1,644.00

Last 5 Year EPS CAGR: -33.84%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 22.71%, which is a positive sign.
  2. The company has higher reserves (1,060.50 cr) compared to borrowings (34.88 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (434.13 cr) and profit (282.50 cr) over the years.
  1. The stock has a high average Working Capital Days of 189.71, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 352.43, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Concord Biotech Ltd:
    1. Net Profit Margin: 29.96%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 26.41% (Industry Average ROCE: 27.9%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 20.18% (Industry Average ROE: 20.9%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 120.41
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 4.84
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 52.4 (Industry average Stock P/E: 52.4)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Concord Biotech Ltd. is a Public Limited Listed company incorporated on 23/11/1984 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24230GJ1984PLC007440 and registration number is 007440. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 1016.94 Cr. and Equity Capital is Rs. 10.46 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
Pharmaceuticals1482-1486, Trasad Road, Dholka, Ahmedabad Gujarat 382225complianceofficer@concordbiotech.com
http://www.concordbiotech.com
Management
NamePosition Held
Mr. Sudhir VaidChairman & Managing Director
Mr. Ankur VaidJoint Managing Director & CEO
Mr. Ravi KapoorNon Executive Director
Mr. Rajiv Ambrish AgarwalNon Executive Director
Mrs. Bharti KhannaIndependent Director
Mr. Amitabh ThakoreIndependent Director
Mr. Arvind AgarwalIndependent Director
Mr. Jayaram EaswaranIndependent Director
Dr. Mandayam Chakravarthy SriramanIndependent Director

FAQ

What is the latest intrinsic value of Concord Biotech Ltd?

The latest intrinsic value of Concord Biotech Ltd as on 12 March 2025 is ₹1338.77, which is 18.57% lower than the current market price of 1,644.00, indicating the stock is overvalued by 18.57%. The intrinsic value of Concord Biotech Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹17,200 Cr. and recorded a high/low of ₹2,664/1,327 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹1,580 Cr and total liabilities of ₹1,765 Cr.

What is the Market Cap of Concord Biotech Ltd?

The Market Cap of Concord Biotech Ltd is 17,200 Cr..

What is the current Stock Price of Concord Biotech Ltd as on 12 March 2025?

The current stock price of Concord Biotech Ltd as on 12 March 2025 is ₹1,644.

What is the High / Low of Concord Biotech Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Concord Biotech Ltd stocks is ₹2,664/1,327.

What is the Stock P/E of Concord Biotech Ltd?

The Stock P/E of Concord Biotech Ltd is 52.4.

What is the Book Value of Concord Biotech Ltd?

The Book Value of Concord Biotech Ltd is 152.

What is the Dividend Yield of Concord Biotech Ltd?

The Dividend Yield of Concord Biotech Ltd is 0.53 %.

What is the ROCE of Concord Biotech Ltd?

The ROCE of Concord Biotech Ltd is 27.9 %.

What is the ROE of Concord Biotech Ltd?

The ROE of Concord Biotech Ltd is 20.9 %.

What is the Face Value of Concord Biotech Ltd?

The Face Value of Concord Biotech Ltd is 1.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Concord Biotech Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE